Methods of treating inflammation associated airway diseases and viral infections
View Patent ↗The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
1. A method of treating an acute influenza virus-induced lung infection in a subject, said method comprising the step of administering a composition consisting essentially of an anti-S100A9 antibody to the subject,
wherein the anti-S100A9 antibody additionally reduces acute influenza virus-induced lung inflammation in the subject.
2. The method of claim 1 , wherein the influenza virus is influenza A.
3. The method of claim 2 , wherein influenza A is an influenza A serotype selected from the group consisting of H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, and H7N9.
4. The method of claim 1 , wherein the composition is administered to the subject via a route selected the group consisting of inhalation to the respiratory system, instillation in the respiratory system, intraperitoneal injection, and intravenous injection.
5. The method of claim 1 , wherein the anti-S100A9 antibody is a humanized anti-S100A9 antibody.
6. The method of claim 1 , wherein the anti-S100A9 antibody is a S100A9-binding antibody fragment or an antibody conjugate.
7. The method of claim 1 , wherein the anti-S100A9 antibody reduces apoptosis in one of more lungs of the subject.
8. The method of claim 1 , wherein the administration of the composition reduces activation of the TLR4-MyD88 pathway in the subject.
9. The method of claim 1 , wherein the administration of the composition reduces TNF-α in a lung of the subject.
10. The method of claim 1 , wherein the administration of the composition reduces IL-6 in the subject.
11. A method of treating an acute influenza virus-induced lung infection in a subject, said method comprising the step of administering a composition consisting of an anti-S100A9 antibody to the subject,
wherein the anti-S100A9 antibody additionally reduces acute influenza virus-induced lung inflammation in the subject.
12. The method of claim 11 , wherein the influenza virus is influenza A.
13. The method of claim 12 , wherein influenza A is an influenza A serotype selected from the group consisting of H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, and H7N9.
14. The method of claim 11 , wherein the composition is administered to the subject via a route selected the group consisting of inhalation to the respiratory system, instillation in the respiratory system, intraperitoneal injection, and intravenous injection.
15. The method of claim 11 , wherein the anti-S100A9 antibody is a humanized anti-S100A9 antibody.
16. The method of claim 11 , wherein the anti-S100A9 antibody is a S100A9-binding antibody fragment or an antibody conjugate.
17. The method of claim 11 , wherein the anti-S100A9 antibody reduces apoptosis in one of more lungs of the subject.
18. The method of claim 11 , wherein the administration of the composition reduces activation of the TLR4-MyD88 pathway in the subject.
19. The method of claim 11 , wherein the administration of the composition reduces TNF-α in a lung of the subject.
20. The method of claim 11 , wherein the administration of the composition reduces IL-6 in the subject.